Title : Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

Pub. Date : 2010 Jul

PMID : 20520639






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens